-
Mashup Score: 0Development of LAVA-1207 Discontinues in mCRPC - 7 hour(s) ago
The development of LAVA-1207 for metastatic castration-resistant prostate cancer has been discontinued.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Rapid, At-Home PSA Screening Test Gains Approval in UAE for Early Detection of Prostate Cancer - 8 hour(s) ago
The Fortel PSA Screening Test has been approved by the United Arab Emirates MOHAP for the rapid detection of early signs of prostate cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The United Arab Emirates Ministry of Health and Prevention has approved the Fortel® PSA Screening Test for the rapid, at-home detection of early indicators of prostate cancer. #pcsm #oncology #MedTwitter https://t.co/Gd42xCRvUz https://t.co/nQ5FUGBbz8
-
-
Mashup Score: 0My New Year’s Resolution After A Testicular Cancer Diagnosis - 9 day(s) ago
My New Year’s resolutions have evolved from seeking external goals to embracing personal growth and appreciating each day.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
My New Year’s Resolution After A Testicular Cancer Diagnosis #pcsm #Oncology #MedTwitter https://t.co/OxOTU5mLKn
-
-
Mashup Score: 0My New Year’s Resolution After A Testicular Cancer Diagnosis - 17 day(s) ago
My New Year’s resolutions have evolved from seeking external goals to embracing personal growth and appreciating each day.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
My New Year’s Resolution After A Testicular Cancer Diagnosis #pcsm #Oncology #MedTwitter https://t.co/OxOTU5mLKn
-
-
Mashup Score: 2
Researchers will investigate aggressive prostate cancer from a mechanistic, biomarker and therapeutic perspective.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
UCSF Prostate Cancer Program Awarded SPORE Grant by National Cancer Institute @UCSFCancer #pcsm #oncology #MedTwitter https://t.co/DenjCkTXvn
-
-
Mashup Score: 4Retrospective Study Reveals Enzalutamide Yields More Favorable Outcomes vs Abiraterone in mCRPC - 5 month(s) ago
Enzalutamide led to improved OS, PCS, TTS, and TTR vs abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Retrospective Study Reveals Enzalutamide Yields More Favorable Outcomes vs Abiraterone in mCRPC @VABostonHC @JAMANetworkOpen #pcsm #oncology #medtwitter https://t.co/HZ3mG2vNgc
-
-
Mashup Score: 4Retrospective Study Reveals Enzalutamide Yields More Favorable Outcomes vs Abiraterone in mCRPC - 5 month(s) ago
Enzalutamide led to improved OS, PCS, TTS, and TTR vs abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Retrospective Study Reveals Enzalutamide Yields More Favorable Outcomes vs Abiraterone in mCRPC @VABostonHC @JAMANetworkOpen #pcsm #oncology #medtwitter https://t.co/HZ3mG2vNgc
-
-
Mashup Score: 4Retrospective Study Reveals Enzalutamide Yields More Favorable Outcomes vs Abiraterone in mCRPC - 6 month(s) ago
Enzalutamide led to improved OS, PCS, TTS, and TTR vs abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Retrospective Study Reveals Enzalutamide Yields More Favorable Outcomes vs Abiraterone in mCRPC @VABostonHC @JAMANetworkOpen #pcsm #oncology #medtwitter https://t.co/HZ3mG2vNgc
-
-
Mashup Score: 2340B Drug Pricing Program Ostensibly Improves Cancer Care but Carries Unforeseen Consequences - 7 month(s) ago
Kassem Faraj, MD, details the 340B Drug Pricing program and data from a study examining participation in the program for patients with advanced prostate cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
340B Drug Pricing Program Ostensibly Improves Cancer Care but Carries Unforeseen Consequences @KassemFarajMD @UMichUrology #pcsm #oncology #MedTwitter https://t.co/cDSgOwHGgT
-
-
Mashup Score: 2
The addition of pembrolizumab (Keytruda) to enzalutamide (Xtandi) and androgen deprivation therapy did not improve radiographic progression-free survival vs placebo plus enzalutamide and ADT in patients with metastatic hormone-sensitive prostate cancer, according to data from the phase 3 KEYNOTE-991 trial presented at the 2023 ESMO Congress.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Pembrolizumab Plus Enzalutamide/ADT Fails to Improve rPFS in mHSPC #pcsm #oncology #MedTwitter https://t.co/pClfPslD0u
-
The development of LAVA-1207 as a potential treatment option for patients with PSMA–positive metastatic castration-resistant prostate cancer has been discontinued. #pcsm #oncology #MedTwitter https://t.co/zInlVKSXDx https://t.co/WZy3SLCKLG